OTC$LIANY
Lianbio-Adr · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
LianBio reported results for the third quarter of 2022 and provided a corporate update.
LianBio reported a net loss of $21.9 million for the third quarter of 2022, compared to a net loss of $13.1 million for the third quarter of 2021. The company's cash balance was $331.8 million at the end of the third quarter of 2022, which is expected to fund operations into the second half of 2024.
- Enrollment completed in registrational Phase 3 EXPLORER-CN trial of mavacamten, with data expected mid-2023.
- Pivotal Phase 3 LIBRA trial of TP-03 for the treatment of Demodex blepharitis initiated in China, with data expected in the fourth quarter of 2023.
- Pivotal Phase 3 NANORAY-312 trial of NBTXR3 for the treatment of head & neck cancer initiated in Asia.
- Cash balance of $331.8 million at the end of third quarter 2022 with runway into the second half of 2024.
Headline financials
Revenue & EPS history
Lianbio-Adr · Revenue · Quarterly
$0
Forward guidance
LianBio anticipates several key milestones in 2023, including topline data from Phase 3 trials for mavacamten and TP-03, and initiation of a Phase 1 trial for BBP-398 in combination with an EGFR-inhibitor.
Tailwinds
- Topline data from the Phase 3 EXPLORER-CN trial of mavacamten is expected in mid-2023.
- Topline data from the Phase 3 LIBRA trial of TP-03 is expected in the fourth quarter of 2023.
- Topline data from the ongoing Phase 2a clinical trial of infigratinib is expected in the second half of 2023.
- A Phase 1 clinical trial of BBP-398 in combination with an EGFR-inhibitor in non-small cell lung cancer is expected to be initiated in the first half of 2023.
- Mavacamten patient education and physician awareness activities are underway in China.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q3 2022
+8.4%
Avg return
Earnings day
+8.4%
Avg return
5 days after
-3.1%
Avg return
30 days after
77%
10 / 13 earnings
Positive
+17.7%
Q4 2020
Best reaction
-4.1%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2024 | -2.2% | -6.7% | -7.4% | |
| Q3 2023 | +0.7% | +1.5% | +4.2% | |
| Q2 2023 | +2.7% | +0.0% | -9.7% | |
| Q1 2023 | -4.1% | +4.6% | +17.7% | |
| Q4 2022 | -1.2% | +17.4% | +18.0% | |
| Q3 2022 | +17.5% | +38.9% | +7.1% | |
| Q2 2022 | +11.1% | -1.5% | -3.0% | |
| Q1 2022 | +9.3% | +29.8% | +28.4% | |
| Q4 2021 | +3.9% | +26.1% | +7.3% | |
| Q2 2021 | +17.7% | +0.4% | -17.3% | |
| Q3 2021 | +17.7% | +0.4% | -17.3% | |
| Q4 2020 | +17.7% | +0.4% | -17.3% | |
| Q1 2021 | +17.7% | -2.4% | -50.4% | |
| Q3 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro